VentureMed Group Secures $28 Million to Enhance FLEX Vessel Prep System for Vascular Disease Treatment

VentureMed Group Secures $28 Million for FLEX Vessel Prep System

In an impressive move signaling investor confidence, VentureMed Group, Inc. has closed a Series C funding round amounting to $28 million, aimed at enhancing the commercial traction of its FLEX Vessel Prep™ System. This financing round was led by S3 Ventures and included contributions from previous investors like Endeavour Vision. This substantial investment highlights the growing importance of innovative approaches to vascular health, particularly as this field faces mounting challenges.

Denis Harrington, the President and CEO of VentureMed, expressed gratitude for the support of returning investors while welcoming new partners into the fold. He emphasized that this funding would not only bolster the company’s commercial infrastructure but would also advance its clinical programs and innovation pipeline. With this financial backing, VentureMed is poised to address the global burden of vascular diseases that are increasingly linked to the rise in obesity, diabetes, and hypertension.

Vascular diseases, particularly Peripheral Arterial Disease (PAD), pose significant health challenges worldwide, affecting over 20 million individuals in the U.S. and over 200 million globally. Recognizing this urgency, VentureMed is dedicated to revolutionizing vascular access through its advanced technologies, specifically the FLEX Vessel Prep™ System. This system is recognized for its potential to improve vessel compliance and reduce trauma during treatment, ultimately leading to better long-term health outcomes.

Dr. Ari Kramer, a General Surgeon at Spartanburg Medical Center, noted that lesion preparation is an essential procedure in enhancing patient outcomes in vascular care. He underscored the importance of the FLEX Vessel Prep System in addressing interventions for arteriovenous access. The recent fundraising effort represents a critical step forward as the company continues to build clinical evidence and explore broader indications for its technologies.

The FLEX Vessel Prep System, which is FDA 510(k)-cleared and has received CE Mark approval, has already shown its potential through dedicated pathways for reimbursement in the U.S. by acquiring a unique CMS HCPCS code (C1600). This paves the way for redefining how vessel preparation is approached within the medical community, with implications for expanded treatment options on a global scale.

The cycle of re-narrowing in vascular disease can impose significant burdens on both patients and healthcare systems. Alexander Schmitz, a Partner at Endeavour Vision, highlighted how a technology designed to minimize the need for reinterventions aligns perfectly with the evolving landscape of value-based care. He expressed enthusiasm for continued collaboration with VentureMed in its mission to expand access to transformative therapies.

The FLEX Vessel Prep™ System employs a unique technique called Kinetic Endovascular Micro-incision Creation (KEMIC). This novel approach contrasts with traditional balloon methods by utilizing dynamic vessel apposition to create precise micro-incisions, ultimately enhancing drug uptake during combination therapy and reducing the risk of restenosis.

The implications of this investment extend beyond immediate clinical applications; it denotes a shift towards improving healthcare standards for patients suffering from vascular diseases. As VentureMed forges ahead with this crucial funding, the future of the FLEX Vessel Prep System looks promising, with the potential to transform vascular access and treatment standards across varying patient populations.

In conclusion, VentureMed Group's successful funding round not only inspires confidence in its advanced medical technologies but also addresses a critical need in global healthcare. With backing from influential investors and a commitment to innovation, the company is well-positioned to lead advancements in vascular disease treatment, ultimately improving the lives of millions.

For more information about VentureMed Group and the FLEX Vessel Prep™ System, visit www.VentureMedgroup.com.